Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Items 101–200 of 529
Santiago, J. A., & Potashkin, J. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423573112 · Cited by 102
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 91
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 108
Zheng, M., & Wang, P. (2021) · 3 Biotech · doi:10.1007/s13205-021-02738-3 · Cited by 293
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
Cao, L., Li, D., Feng, P., Li, L., Xue, G.-F., Li, G., & Hölscher, C. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000548 · Cited by 90
Glucose metabolism impairment in Parkinson’s disease
Dai, C., Tan, C., Zhao, L., Liang, Y., Liu, G., Liu, H., Zhong, Y., Liu, Z., Mo, L., Liu, X., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110672 · Cited by 99
System-based approaches to decode the molecular links in Parkinson's disease and diabetes
Santiago, J. A., & Potashkin, J. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.019 · Cited by 95
“These efforts are in part motivated by recent findings that show that drugs to treat diabetic patients may elicit therapeutic effects in patients with PD (Aviles-Olmos et al., 2013a).”
BackgroundDiabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
Sergi, D., Renaud, J., Simola, N., & Martinoli, M.-G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 86
“…patients receiving dopamine-replacing therapy showed that twice-daily injections of exenatide for 12 months improved overnight off-medication motor symptoms and dementia, rated according to the unified PD rating scale and the Mattis dementia rating scale, respectively (Aviles-Olmos et al., 2013).”
BackgroundMethodToll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer’s Disease
Wu, L., Xian, X., Xu, G., Tan, Z., Dong, F., Zhang, M., & Zhang, F. (2022) · Mediators of Inflammation · doi:10.1155/2022/7924199 · Cited by 107
“GLP-1 has demonstrated efficacy in clinical trials in patients with AD [157, 158]; however, GLP-1 undergoes easy degradation, and therefore, continuous intravenous infusions or continuous subcutaneous injections are necessary to perform therapeutic roles, thus limiting its clinical application [154].”
BackgroundCheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84
Neuroendocrine abnormalities in Parkinson's disease
Pablo‐Fernández, E. D., Breen, D. P., Bouloux, P. M., Barker, R. A., Foltynie, T., & Warner, T. T. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314601 · Cited by 96
“63 An initial open label randomised controlled trial comparing 20 patients with PD treated with exenatide and 24 PD patients acting as controls showed a clinically relevant improvement in motor and cognitive domains in the treatment group after 12 months.(64) Further studies with larger samples are currently on going”
BackgroundSelf-citationVijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047993 · Cited by 84
Self-citationGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Santiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 81
“To date, there is no modifying agent or preventive treatment available but commonly prescribed drugs to treat diabetics have shown promise in Parkinson’s disease clinical trials [5,6].”
BackgroundNeuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
Li, Y., Liu, W., Li, L., & Hölscher, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.002 · Cited by 87
“Hence, the treatment to improve insulin resistance for T2DM may be useful for PD patients (Aviles-Olmos et al., 2013b; Holscher, 2014b).”
Jalewa, J., Sharma, M. K., Gengler, S., & Hölscher, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.013 · Cited by 86
“…(Freiherr et al., 2013; Ghasemi et al., 2013; van der Heide et al., 2006), and observed that insulin signaling is ision of Biomedical and Life lege, Lancaster, LA1 4YQ, UK. scher). compromised in the brains of patients with PD (Aviles-Olmos et al., 2013b; Moroo et al., 1994; Morris et al., 2011).”
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
“Crucially, these improvements persisted even after a 2-month washout period, suggesting the potential long-term benefits [96].”
BackgroundYu, D., Moore, S. C., Matthews, C. E., Xiang, Y., Zhang, X., Gao, Y., Zheng, W., & Shu, X. (2015) · Metabolomics · doi:10.1007/s11306-015-0890-8 · Cited by 80
“On the other hand, antidiabetic drugs, such as exenatide, may have neuroprotective effects (Aviles-Olmos et al. 2013).”
BackgroundWhat Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis
Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Skene, S. S., Chowdhury, K., Aviles-Olmos, I., Limousin, P., & Foltynie, T. (2018) · Journal of Parkinson's Disease · doi:10.3233/jpd-181329 · Cited by 77
“observed in the first trial of exenatide in PD patients[18,19] requires further study.”
Self-citationLiraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial
Edison, P., Femminella, G. D., Ritchie, C. W., Nowell, J., Holmes, C., Walker, Z., Ridha, B. H., Raza, S., Livingston, N. R., Frangou, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04106-7 · Cited by 126
“Exenatide treatment improved MDS-UPDRS scores in participants with Parkinson’s disease compared to controls 15,16 .”
Cooper, D. H., Ramachandra, R., Ceban, F., Di Vincenzo, J. D., Rhee, T. G., Mansur, R. B., Teopiz, K. M., Gill, H., Ho, R., Cao, B., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.041 · Cited by 79
Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
Madhusudhanan, J., Suresh, G., & Devanathan, V. (2020) · Brain and Behavior · doi:10.1002/brb3.1577 · Cited by 86
“…(AvilesOlmos et al., 2013) The data that support the findings of this study are openly available in PubMed at https://doi.org/10.1172/ JCI68295 (Aviles-Olmos et al., 2013) Lixisenatide/Adlyxin GLP-1 receptor agonist FDA approved drug for T2DM and in phase II clinical trial for PD…”
BackgroundInfluentialDissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology
Santiago, J. A., Bottero, V., & Potashkin, J. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00166 · Cited by 86
Batista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77
Quansah, E., Peelaerts, W., Langston, J. W., Simon, D. K., Colca, J., & Brundin, P. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0260-x · Cited by 75
“Specifically, exenatide-treated patients exhibited less motor deficits on the Movement Disorders Society Unified Parkinson’s Disease rating scale (MDS-UPDRS, part III) at two months after a” washout” of the treatment, which was the predefined primary endpoint [20].”
BackgroundMethodLong-term oral administration of Exendin-4 to control type 2 diabetes in a rat model
Suzuki, K., Kim, K. S., & Bae, Y. H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.028 · Cited by 75
“Ex-4 has been widely used for T2DM and has great potential as a future therapeutic for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, which are linked to insulin resistance in the brain [7,8].”
BackgroundImpaired brain insulin signalling in Parkinson's disease
Bassil, F., Delamarre, A., Canron, M., Dutheil, N., Vital, A., Négrier‐Leibreich, M., Bezard, E., Fernagut, P., & Meissner, W. G. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12760 · Cited by 73
“For instance, the GLP-1 analogue exenatide has shown positive effects on motor outcomes and cognition in an open-label study of 45 PD patients.(14,15) Subsequently, a randomised placebo-controlled study has shown smaller, yet significant, differences on Unified PD Rating Scale III Off scores.”
BackgroundType 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts
Cullinane, P. W., Pablo‐Fernández, E. D., König, A., Outeiro, T. F., Jaunmuktane, Z., & Warner, T. T. (2022) · Movement Disorders · doi:10.1002/mds.29298 · Cited by 82
Challenges in detecting disease modification in Parkinson's disease clinical trials
Athauda, D. S., & Foltynie, T. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.07.019 · Cited by 82
Self-citationGebauer, M., & Skerra, A. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.016 · Cited by 77
Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 85
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Peng, W., Zhou, R., Sun, Z.-F., Long, J.-W., & Gong, Y.-Q. (2022) · Aging and disease · doi:10.14336/ad.2021.0928 · Cited by 71
“Clinical evidence suggest that a 12 month-exenatide treatment can significantly improve motor and cognitive functions in PD patients [100].”
BackgroundFang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70
Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y.-H., Hoffer, B. J., Miller, J., Lahiri, D. K., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 70
“Maximizing the translational potential of the strategy is clearly crucial, although three GLP-1R agonists have been approved and are well tolerated in type 2 diabetes mellitus [80–84], and are promising clinical studies in PD [158] support repositioning for neurologic disorders.”
InfluentialGLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., & Emsley, H. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990.pub2 · Cited by 69
Self-citationGLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 68
“In the clinical trials involving PD patients (NCT01971242, NCT01174810), 12 months’ treatment with exenatide improved motor and cognitive outcomes [90,91], albeit, these findings have been described as ‘low certainty evidence’ [92].”
BackgroundFuzzati-Armentero, M. T., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 68
“After a positive proof of concept open-label study that suggested significant improvement in both motor and non-motor PD features (240), researchers moved to a double-blind, placebo-controlled trial (241).”
BackgroundDeciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 67
“Evidence from preclinical studies demonstrates that activation of GLP-1R signaling may be neuroprotective (14,18), and a randomized controlled clinical trial of exenatide in human subjects with Parkinson disease (58) provides support for the neuroprotective potential of GLP-1R signaling in human subjects.”
BackgroundPrevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 67
Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
Ji, C., Xue, G.-F., Li, G., Li, D., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0021 · Cited by 68
Parkinson';s Disease, Diabetes and Cognitive Impairment
Ashraghi, M. R., Pagano, G., Polychronis, S., Niccolini, F., & Politis, M. (2016) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214810999160628105549 · Cited by 70
“An open label clinical trial using exenatide in humans demonstrated an improvement in motor and non-motor symptoms in patients with PD, as assessed using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [56].”
BackgroundMethodInfluentialChen, S., Yu, S.-J., Li, Y., Lecca, D., Glotfelty, E., Kim, H. K., Choi, H.-I., Hoffer, B. J., Greig, N. H., Kim, D. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28449-z · Cited by 68
Maskery, M., Goulding, E. M., Gengler, S., Melchiorsen, J. U., Rosenkilde, M. M., & Hölscher, C. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317520953041 · Cited by 66
Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
Song, J., & Kim, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00065 · Cited by 77
Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases
Chen, S., Chuang, Y., Lin, T., & Yang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175439 · Cited by 73
Deciphering Brain Insulin Receptor and Insulin‐Like Growth Factor 1 Receptor Signalling
Kleinridders, A. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12433 · Cited by 65
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“Moreover, evidence for the therapeutic efficacy of peripherally administered exenatide in human subjects with Parkinson’s disease (57) highlights the compelling translational rationale for better understanding how PGDPS interact with the BBB and access the CNS.”
BackgroundMaluf, F. C., Feder, D., & Carvalho, A. A. D. S. (2019) · Parkinson s Disease · doi:10.1155/2019/4951379 · Cited by 73
“[99] Cell culture studies: Jalewa et al.”
Association between Parkinson's disease and diabetes: Data from NEDICES study
De Pablo-Fernandez, E., Sierra-Hidalgo, F., Benito-León, J., & Bermejo-Pareja, F. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12793 · Cited by 63
Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62
Li, Y., Liu, W., Li, L., & Hölscher, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.050 · Cited by 64
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“…a 12-week washout) and lixisenatide (106 patients, 12 months plus a 2-month washout), reported positive results even after cessation of study medication—usually reported as less deterioration in the motor subscale of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale 42,43 .”
Elgueta, D., Aymerich, M. S., Contreras, F., Montoya, A., Celorrio, M., Rojo-Bustamante, E., Riquelme, E., González, H., Vásquez, M., Franco, R., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.028 · Cited by 67
“Few years later, the drugs were tested in a small cohort (45 patients) and the results encourage additional investment in the expensive double-blind placebocontrolled phase II/III studies required for approval as medicaments (Aviles-Olmos et al., 2013; Foltynie and Aviles-Olmos, 2014).”
BackgroundPanagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 61
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 60
Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes
Palleria, C., Leporini, C., Maida, F., Succurro, E., Sarro, G. D., Arturi, F., & Russo, E. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.07.002 · Cited by 66
Renaud, J., Bassareo, V., Beaulieu, J., Pinna, A., Schlich, M., Lavoie, C., Murtas, D., Simola, N., & Martinoli, M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.010 · Cited by 61
Ferreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
Mattson, M. P. (2014) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130335 · Cited by 59
“Because exercise and dietary energy restriction improve insulin sensitivity and are neuroprotective [41] [114], it is reasonable to consider that drugs that increase insulin sensitivity might be beneficial for PD patients.”
Drug Repurposing in Parkinson’s Disease
Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 62
Self-citationTweedie, D., Rachmany, L., Rubovitch, V., Li, Y., Holloway, H. W., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Hoffer, B. J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.489 · Cited by 58
“Based on this preclinical data, and clinical trials of Ex-4 ongoing in both Parkinson’s disease and Alzheimer’s disease [23,72,73], further explorations of such agents in diverse animal models of B-TBI may help to define possible treatment options for clinical TBI–induced neurodegenerative dementia.”
BackgroundMethodOnoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 57
Acylated but not des‐acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease
Bayliss, J. A., Lemus, M., Santos, V. V., Deo, M., Elsworth, J. D., & Andrews, Z. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13576 · Cited by 56
“Since this initial discovery, the GLP1 agonist Exenatide has proven to be clinically effective in reducing disease progression (Aviles-Olmos et al. 2013).”
BackgroundVentorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171068 · Cited by 56
“Results from an initial, single-blinded study in PD suggest that exendin-4 reduces rate of motor and cognitive deterioration following a one year treatment period [20] and that this effect is sustained for at least an additional year following cessation of treatment [21].”
BackgroundInfluentialInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
McGhee, D. J. M., Ritchie, C. W., Zajicek, J., & Counsell, C. E. (2016) · BMC Neurology · doi:10.1186/s12883-016-0606-3 · Cited by 66
“In one study [16], only fluctuating patients on symptomatic treatment were included and assessments were made in a practically defined off phase after 12–24 h drug withdrawal.”
BackgroundMethodLee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 55
Perez‐Lloret, S., Nègre‐Pagès, L., Damier, P., Delval, A., Derkinderen, P., Destée, A., Meissner, W. G., Tison, F., Rascol, O., & of the COPARK Study Group (2017) · European Journal of Neurology · doi:10.1111/ene.13466 · Cited by 55
Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy
Bu, L.-L., Liu, Y., Shen, Y., Fan, Y., Yu, W., Jiang, D., Tang, Y., Yang, Y., Wu, P., Zuo, C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01018-5 · Cited by 59
Wang, R.-F., Xue, G., Hölscher, C., Tian, M.-J., Feng, P., Zheng, J.-Y., & Li, D. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.03.009 · Cited by 58
“In addition, the GLP-1 receptor agonist exendin-4 has shown good protective effects in a pilot study in Parkinson’s patients [48, 49].”
BackgroundInsulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease
Mejido, D. C. P., Peny, J. A., Vieira, M. N. N., Ferreira, S. T., & Felice, F. G. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108115 · Cited by 54
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned
Hung, A. Y., & Schwarzschild, M. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00964-w · Cited by 55
“Apparent benefits were reported to persist in motor and cognitive function at 14 months, despite patients being off exenatide during a 2-month washout period [85].”
BackgroundStevens, K. N., Creanor, S., Jeffery, A., Whone, A. L., Zajicek, J., Foggo, A., Jones, B., Chapman, R., Cocking, L., Wilks, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3718 · Cited by 59
Rocha‐Ferreira, E., Poupon-Bejuit, L., Zelco, A., Leverin, A., Nair, S., Jonsdotter, A., Carlsson, Y., Thornton, C., Hagberg, H., & Rahim, A. A. (2018) · Brain · doi:10.1093/brain/awy220 · Cited by 51
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2079492 · Cited by 50
“This demonstrates the diseasemodifying properties of exendin-4 and the outcomes were convincing enough that Bydureon was subsequently evaluated in a similar group of PD participants for 60 weeks in a double-blind clinical trial initiated by the same investigators (NCT01971242) [76].”
BackgroundMethodResultInfluentialYu, H., Sun, T., He, X., Wang, Z., Zhao, K., An, J., Wen, L., Li, J., Li, W., & Feng, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.0325 · Cited by 57
“They found that exenatide can improve motor and cognitive functions, which persists even 12 months after its discontinuation [160, 161].”
BackgroundWang, Y., Chen, W., Han, Y., Xu, X., Yang, A., Wei, J., Hong, D., Fang, X., & Chen, T. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10505 · Cited by 58
“22,23 Liraglutide, with a 97% homology and a 13-h half-life, is the first GLP-1R agonist derived from natural GLP-1.”
Incretin-based therapies: where will we be 50 years from now?
Meier, J. J., & Nauck, M. A. (2015) · Diabetologia · doi:10.1007/s00125-015-3608-6 · Cited by 58
“Recently, improvements in memory and movement disorders have also been reported in patients with Parkinson’s disease, thus revealing a therapeutic potential for the incretin-based therapies in this field [22].”
BackgroundNeuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease
Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 55
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
Zhang, Y., Chen, Y., Li, L., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.021 · Cited by 51
Foltynie, T., & Aviles-Olmos, I. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.005 · Cited by 49
“Results The detailed results of our open-label, proof-of-concept trial have been reported separately [50].”
BackgroundSelf-citationMorris, L. C., Nance, K. D., Gentry, P. R., Days, E. L., Weaver, C. D., Niswender, C. M., Thompson, A. D., Jones, C. K., Locuson, C. W., Morrison, R. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501375c · Cited by 47
Sekar, S., & Taghibiglou, C. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.049 · Cited by 49
“Epidemiological and clinical studies showed that PD and type 2 diabetes are associated with similar dysregulation in glucose and energy metabolism [3, 4], suggesting that glucose metabolism alteration may be the earlier event in the pathogenesis of PD [5].”
Lin, T.-K., Lin, K.-J., Lin, H.-Y., Lin, K.-L., Lan, M.-Y., Wang, P.-W., Wang, T.-J., Wang, F.-S., Tsai, P.-C., Liou, C.-W., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 49
Hölscher, C. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.955258 · Cited by 48
“2point improvement in the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) part 3 in the drug group compared to controls (Aviles-Olmos et al., 2013).”
BackgroundTherapeutic innovation in drug repurposing: Challenges and opportunities
Recino, A., Rayner, M., Rohn, J. L., Pasqua, O. E. D., Recino, A., Rayner, M. L. D., Rohn, J. L., Carter, B., Cupani, A., Dahlmann-Noor, A. H., et al. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104390 · Cited by 62
Self-citationIncretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar-y-Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48
5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease
Scholpa, N. E., Lynn, M. K., Corum, D. G., Boger, H. A., & Schnellmann, R. G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14076 · Cited by 51
“This, in combination with the variability of the pathophysiology of the disease between patients, is a potential explanation for why the limited number of clinical trials that have investigated mitochondrial biogenic compounds for the treatment of Parkinson’s disease have not provided conclusive positive results (Avil…”
BackgroundRebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving
Haas, J., Berg, D., Bosy‐Westphal, A., & Schaeffer, E. (2022) · Nutrients · doi:10.3390/nu14153240 · Cited by 57
“GLP-1 agonists Improvement of motor function [84–89] Improvement of neuronal inflammation [84,88,90] Increased neuroprotection [84,86,88–93] Increased anti-oxidant effect [90] Decreased alpha-synuclein aggregation [88] Improvement mitochondrial function [88,93] Improvement of cognitive function [94,95] Improvement of…”
BackgroundTherapies modulating insulin resistance in Parkinson’s disease: A cross talk
Sharma, T., Kaur, D., Grewal, A. K., & Singh, T. G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135754 · Cited by 44
Hölscher, C. (2014) · PubMed · Cited by 55
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 44
Self-citationGiuntini, M., Baldacci, F., Prete, E. D., Bonuccelli, U., & Ceravolo, R. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.016 · Cited by 44
Zhang, L., Li, C., Zhang, Z., Zhang, Z., Jin, Q., Li, L., & Hölscher, C. (2022) · Parkinson s Disease · doi:10.1155/2022/1428817 · Cited by 60
“A pilot clinical trial in PD patients (NCT01174810) had shown good efects [39, 40], and a follow-up phase II placebo-controlled clinical trial con-frmed the protective efects in PD patients [41, 42].”
Lisco, G., Tullio, A. D., Iovino, M., Disoteo, O., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2023) · Biomedicines · doi:10.3390/biomedicines11112993 · Cited by 54
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.